The Patent Finder

Euroscreen S.A.

Also on record
Records under this name other than patents Euroscreen S.A. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Back to Euroscreen S.A.

PatentTitleStatus Expires Confidence
US 7,824,866Ligand for G-protein coupled receptor GPR72 and uses thereof
Formerly held
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,497,075Methods of identifying a modulator that inhibits the binding between Epstein-Barr Virus induced receptor 2 and cholesterol derived ligands
Formerly held
In force
 · High confidence
In forceHigh confidence
US 8,871,761NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
Formerly held
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,926,325NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
Formerly held
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,065,960NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
Formerly held
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,695,120Substituted pyrrolidines as G-protein coupled receptor 43 agonists
Formerly held
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,475,814Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof
Formerly held
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,065,961Chiral N-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof
Formerly held
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,840,508N-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a] pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders
Formerly held
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,969,738N-acyl-(3-substituted)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders
Formerly held
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 53 patents shown.
Pro members see all 53.
Pro members: see all 53 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited